DocumentsDate added
Original article:-
Laila Mahmoud Matalqah*1,2 , Khaldoon Mahmoud Radaideh3 , Syed Azhar Syed Sulaiman1 , Mohamed Azmi Hassali4 & Muhamad Ali Sk Abdul Kader5
Affiliation:-
Laila Mahmoud Matalaqah (M.Pharm, clinical pharmacy) PhD Candidate, 1Displine of Clinical Pharmacy, School of Pharmaceutical sciences, Universiti Sains Malaysia (USM),2School of Pharmacy, Allianze University College of Medical Sciences (AUCMS), Kepala Batas, Malaysia. Dr. Khaldoon Mahmoud Radaideh (PhD), School of Medical Imaging and Radiotherapy, 3Allianze University College of Medical Sciences (AUCMS), Kepala Batas, Malaysia Prof. Dr. Syed Azhar Syed Sulaiman, PhD. Clinical Pharmacy, 1Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences Universiti Sains Malaysia (USM), Penang, Malaysia. Assoc. Prof. Dr. Mohamed Azmi Ahmad Hassali (Ph.D. Clinical. Pharm), Deputy Dean (Student Affairs & Networking) 4School of Pharmaceutical Sciences, Universiti Sains Malaysi a (USM), Penang, Malaysia. Dr. Muhamad Ali Sk Abdul Kader, MD (USM) MRCP (UK) CMIA FACC (USA)FNHAM, Consultant 5Cardiologist, Department Of Cardiology, Penang Hospital, Malaysia.
Abstract:- Objective: To relate the level of patients’ knowledge about warfarin to their anticoagulation control using a translated Malaysian version of Oral Anticoagulation Knowledge (OAK) Test. Methods: A prospective, cross-sectional study design and methodology were used to elaborate the study data. 382 consecutive outpatients with atrial fibrillation undergoing oral anticoagulant were identified between September 2011 and January 2013 at Hospital Pulau Pinang and Seberang Jaya Hospital, Penang, Malaysia. A standard translation procedure was used to develop the Malaysian version of the 20- question-OAK test from the original English version. Medical records were reviewed for INR levels and other clinical data. To determine the correlation between INR control and warfarin knowledge, spearman correlation analysis was used. Significant was defined as P <0.05. Results: Only 215 were eligible and accepted to complete the questionnaires. The mean±SD of OAK scores was 47.6±17.6. Good internal consistency was found (Cronbach’s alpha = 0.767); and the test-retest reliability value was 0.871 (p<0.001). Data from the Spearman’s rho analyses revealed a statistically significant positive but weak correlation between patients’ knowledge and the number of INR values that were within the therapeutic range Conclusion: A significant relationship between OAK categories and TTR (INR) categories (p <0.05) was found. The Malaysian version of the OAK had a moderate sensitivity and specificity, 58.3% and 58.0%, respectively, with good predictive validity.
Key Words:- anticoagulation, warfarin, patient knowledge, Malaysian version.
References:
1.Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns J A, Joyner C. Canadian Atrial Fibrillation Anticoagulation Study. J Am Coll Cardiol 1991; 18:349-55.
2.Ezekowitz MD, Bridgers SL, James KE. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
3.Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–67.
4.Faridah AMY, Sivasampu S, Lian LM, Hazimah H, Kok LC, & Chinniah RJ. Malaysian Statistics on Medicine 2007. A publication of the Pharmaceutical Services Division and the Clinical Research Centre, The National Medicines Use Survey, Ministry of Health Malaysia, 2010.
5.Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest 2008; 133:160S-198S.
6.Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095-1106.
7.Greenblatt DJ, & von Moltke LL. Interaction of warfarin with drugs, natural substances and foods. JClin Pharmacol 2005;45:127-32.
8.Taylor FC, Ramsay ME, Tan G, Gabbay J, Cohen H. Evaluation of patients knowledge about anticoagulation treatment. Qual Health Care 1994;3(2):7985.
9.Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulation therapy. Haematologica 2002; 87(10):1081-86.
10.Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of Anticoagulation Therapy in Well-informed Older Patients. Arch Intern Med 2004; 164:2044-50.
11.Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126:557-64.
12.Zeolla MM, Brodeur MR, Dominelli A, Haines ST, Allie ND. Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test. Ann Pharmacother 2006;40(4):633-8.
13.Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 2003;37:34-9.
14.Barcellona D, Contu P, Marongiu F. A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control. J Thromb Thrombolysis 2006; 22:185-90.
15.Jank S, Bertsche T, Herzog W, Haefeli WE. Patient knowledge on oral anticoagulants: results of a questionnaire survey in Germany and comparison with the literature. Int J Pharmacol Ther 2008; 46(6):280-8.
16.Roche-Nagle G, Chambers F, Nanra J, et al. Evaluation of patient knowledge regarding oral anticoagulants. Ir Med J 2003; 96(7): 211-3.
17.McCabe PJ, Schad S, Hampton A, Holland DE. Knowledge and self-management behaviors of patients with recently detected atrial fibrillation. Heart Lung 2008;37(2):79-90.
18.Pernod G, Labarère J, Yver J, et al. EDUC’AVK: Reduction of Oral Anticoagulant-related Adverse Events after Patient Education: A Prospective Multicenter Open Randomized Study. J Gen Intern Med 2008; 23(9):1141-6.
19. Hasan SS, Shamala R, Syed IA. et al. Factors Affecting Warfarin-Related Knowledge and INR Control of Patients Attending Physician- and Pharmacist Managed Anticoagulation Clinics. J Pharm Prac 2011.DOI: 10.1177/0897190011415684.
20.Yahaya AHM, Hassali MA, Awaisu A, Shafie AA. Factors associated with warfarin therapy knowledge and anticoagulation control among patients attending a warfarin clinic in Malaysia. J Clin Diag Res 2009; 3:1663-70
21.Devellis RF. Scale development: theory and applications. Newbury Park, CA: Sage Publications, 1991. 22.Kline P. A handbook of test construction: introduction to psychometric design. New York: Methuen & Co, 1986.
23.Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. New York: Oxford University Press, 1989.
24.Briggs AL, Jackson TR, Bruce S, Shapiro NL. The development and performance validation of a tool to assess patient anticoagulation knowledge. Res Social Adm Pharm 2005;1(1):40-59.
25.Winans AR, Rudd KM, Triller D. Assessing anticoagulation knowledge in patients new to warfarin therapy. Ann Pharmacother 2010; 44(7-8):1152-7.
26.Khudair IF, Hanssens YI. Evaluation of patients’ knowledge on warfarin in outpatient anticoagulation clinics in a teaching hospital in Qatar. Saudi Med J 2010; 31(6)672-7.
27.Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health- related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46:1417-32.
28.Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8: 94-104
29.ACCF/AHA/HRS Guideline. Management of Patients with Atrial Fibrillation. Circulation 2011;123:104–23 and 1161–7.
30.Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-9.
31.Connolly SJ, Pogue J, Eikelboom J, Flaker G. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-37.
32.Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: A record linkage study in a large British population. Heart 2005; 91:472–7.
33.Veeger NJ, Piersma-Wichers M, Tijssen JGP, Hillege HL, Meer J. Individual time within target range in patients treated with Vitamin K antagonists: Main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:513-19.
34.White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007; 167:239-45.
35.Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Joint Commission on Accreditation of Healthcare Organizations 2009;35(3):146-55
36.Nunnally JC, Bernstien IH. Psychometric Theory, 3rd ed. New York: McGraw-Hill, 1994.
37. Hu A, Chow C, Dao D, Errett L, Keith M. Factors Influencing Patient Knowledge of Warfarin Therapy After Mechanical Heart Valve Replacement. J Cardiovascular Nurs 2006; 21(3):169-75.
38.Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of Adherence, Knowledge, and Quality of Life on Anticoagulation Control. Ann Pharmacother 2005;39:632-6.
39.The Newcastle Anticoagulation Study Group (Group TNAS). Effectiveness of anticoagulation among patients discharged from hospital on warfarin. MJA 1998; 169:243-46.
40.Smith MB, Christensen N, Wang S, et al. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology 2010; 116:61-9.
41.McCormack PM, Stinson JC, Hemeryck L, Feely J. Audit of an anticoagulant clinic: doctor and patient knowledge. Ir Med J 1997; 90(5):192-3.
42.Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients' perspectives on taking warfarin: qualitative study in family Practice BMC. Fam Pract 2004;5(15).
43.Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: Effects of an educational intervention programme. Int J Cardiol 2006; 110:354-8.
44.St-Louis L, Robichaud-Ekstrand S. Knowledge level and coping strategies according to coagulation levels in older persons with atrial fibrillation. Nurs Health Sci 2003; 5:67-75.
45.Cheah GM, Martens KH. Coumadin Knowledge Deficits: Do Recently Hospitalized Patients Know How to Safely Manage the Medication? Home Healthc Nurse 2003;21(2):94-100.
46.Baker WJ, Pierce KL, & Ryals CA. INR goal attainment and oral anticoagulation knowledge of patients enrolled in an anticoagulation clinic in a Veterans Affairs Medical Center. J Manag Care Pharm 2011,17 (2),133-42.
47.Fang MC, Machtinger EL, Wang F, & Schillinger D. Health literacy and anti- coagulation-related outcomes among patients taking warfarin. J Gen Inter Med, 2006, 21(8), 841-6.
*Correspondence address:
Laila Mahmoud Ali Matalqah.,
Displine of Clinical Pharmacy,
School of Pharmaceutical Sciences, Minden, 11800, Universiti Sains Malaysia (USM),Malaysia.
lmatalqah@yahoo.com, lailamatalqah@allianzeunicollege.edu.my
Telephone:-0060175029392
Original article:- Physiology
Ritabrata Banerjee1, Anup Kumar Ghosh2, Balaram Ghosh3 & Amal Chandra Mondal1*
1Senior Research Fellow (SERB Project), 1*Assistant Professor in Physiology, Raja Peary Mohan College, Uttarpara, Hooghly, University of Calcutta, West Bengal-712258,India.
2Assistant Professor in Instrumentation Science, Jadavpur University, Kolkata, West Bengal-700032, India. 3Assistant Professor in Pharmacology, Calcutta Medical College and Hospital, Kolkata, West Bengal-700072, India.
Abstract:- Objectives: Stress-induced helplessness in rodents constitutes a well-defined model to investigate neurobiological mechanism of depression. In the present investigation, we investigated the correlation between stress induced helplessness and BDNF, its receptor TrkB with two of its principal downstream signaling molecule ERK1, 2 and Akt. Background: Brain-derived neurotrophic factor (BDNF) regulates many physiological functions in the brain, alteration of which has been well associated with the pathogenesis of depression. Materials and Methods: BDNF level was measured by Sandwich ELISA and its cognate receptor TrkB and downstream molecules ERK 1, 2, Akt were assayed by Western blot. Results: Chronic stressed rats exhibited down regulation of BDNF and TrkB along with ERK1, 2 and Akt. This parallels with the decreased escape behavior. The antidepressant drug Fluoxetine hydrochloride (FLX) treated rats exhibited significant increase in escape deficit in stress induced Learned helplessness (LH). This was correlated with the restoration of BDNF levels, its cognate receptor TrkB and expression of its down stream signaling molecules ERK1, 2 and Akt in hippocampus of rat brain. Conclusion: This supports the notion that pharmacological restoration of BDNF and its receptor TrkB may be of therapeutic value for the treatment of depression.
Key Words:-Depression, Neurotrophin, BDNF, TrkB, ERK 1, 2, Akt, FLX.
References:-
1.Castren E., Voikar V., Rantamaki T. Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. 2007; 7(1): 18-21.
2.Duman RS., Monteggia LM. A neurotrophic model for stress related mood disorders. Biol. Psychiat. 2006; 59(12): 1116-27.
3.Chalazonitis A. Neurotrophin-3 as an essential signal for the developing nervous system. Mol. Neurobiol. 1996; 12(1): 39-53.
4.Matsumoto T., Rauskolb S., Polack M., Klose J., Kolbeck R., Korte M., Barde YA. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat. Neurosci. 2008; 11(2): 131-3.
5.Nagappan G., Zaitsev E., Senatorov VV. Jr., Yang J., Hempstead BL., Lu B. Control of extracellular cleavage of Pro-BDNF by high frequency neuronal activity. Proc. Natl. Acad. Sci. USA. 2009; 106(4): 1267-72.
6.Yang J., Siao CJ., Nagappan G., Marinic T., Jing D., Mcgrath K., Chen ZY., Mark W., Tessarollo L., Lee FS., Lu B., Hempstead BL. Neuronal release of proBDNF. Nat. Neuroscsi.2009; 12(2): 113-5.
7.Ohl F., Fuchs E. Differential effects of chronic stress on memory processes in the tree shrew. Brain Res Cogn Brain Res. 1999; 7: 379-87.
8.Zhang YM., Yang Q., Xu CT., Li KS., Li WQ. Effects of phenytoin on morphology and structure of hippocampal CA3 pyramidal neurons of rats in chronic stress. Acta Pharmacol Sin. 2003; 24: 403-7.
9. Xu B., Zang K., Ruff NL., Zhang YA., McConnell SK., Stryker MP., Reichardt LF. Cortical degeneration in the absence of neurotrophin signaling: dendritic retraction and neuronal loss after removal of the receptor TrkB. Neuron. 2000; 26: 233–45.
10.Vaidya VA., Siuciak JA., Du F., Duman RS. Hippocampal mossy fibre sprouting induced by chronic electroconvulsive seizures. Neurosci. 1999; 89:157–66.
11.McAllister AK., Katz LC., Lo DC. Neurotrophins and synaptic plasticity. Ann Rev Neurosci. 1999; 22: 295–318. 12.Duman RS., Malberg J., Nakagawa S., D’ Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiat. 2000; 48: 732–9.
13.Shoval G., Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 2005; 15: 319–29.
14.Ambrosini A., Tininini S., Barassi A., Racagni G., Sturani E., Zippel R. cAMP cascade leads to Ras activation in cortical neurons. Brain Res., Mol. Brain Res. 2000; 75: 54– 60.
15.Cai G., Zhen X., Uryu K., Friedman E. Activation of extra cellular signal-regulated protein kinases is associated with a sensitized locomotor response to D(2) dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats. J. Neurosci. 2000; 20: 1849–57.
16.Mukhin YV., Garnovskaya MN., Collinsworth G., Grewal JS., Pendergrass D., Nagai T., Pinckney S., Greene EL., Raymond JR. 5-Hydroxytryptamine1A receptor/Gibetagamma stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of src in Chinese hamster ovary fibroblasts. Biochem. J. 2000; 347 (Pt 1): 61– 7.
17.Valjent E., Corvol JC., Pages C., Besson MJ., Maldonado R., Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci. 2000; 20: 8701– 9.
18.Yuen EC., Mobley WC. Early BDNF, NT-3, and NT-4 signaling events, Exp. Neurol. 1999; 159: 297– 308.
19.Lacroix L., Broersen LM., Weiner I., Feldom J. The effects of excistotoxic lesion of the medial prefrontal cortex on latent inhibition, prepulse inhibition, food hoarding, elevated plus maze, active avoidance and locomotor activity in the rat. Neurosci. 1998; 84: 431-42.
20.Shirayama Y., Chen AC., Nakagawa S., Russell DS., Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J. Neurosci. 2002; 22: 3251–61.
21.Lin Y., Westenbroek C., Bakker P., Termeer J., Liu A., Li X. and Ter Horst GJ. Effects of long-term stress and recovery on the prefrontal cortex and dentate gyrus in male and female rats. Cerebral cortex. 2008; 18: 2762-74.
22.Valentine G., Dow A., Banasr M., Pittman B., Duman R. Differential effects of chronic antidepressant treatment on shuttle box escape deficits induced by uncontrollable stress. Psychopharmacol. 2008; 200: 585-96.
23.Gambarana C., Scheggi S., Tagliamonte A., Tolu P., De Montis MG. Animal models for the study of antidepressant activity. Brain Res Protoc. 2001; 7: 11-20. 24.Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem. 2003; 10: 86–98.
25.Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001; 2: 24–32.
26.Duman RS., Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiat. 2006; 59:1116–27.
27.Russo-Neustadt AA., Beard RC., Huang YM., Cotman CW. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neurosci. 2000; 101: 305–12.
28.Banerjee R, Das M, Mondal AC, Ghosh B, Ghosh AK. Influences of chronic stress and antidepressant treatment on the hippocampal concentrations of macromolecule BDNF (Brain-derived neurotrophic factor) in a rat model of Learned helplessness. Asian Journal of Microbiol. Biotechnology and Environmental Sci. 2011; 13(4): 625-32.
29.Xiao-heng L. Neng-bao L., Min-hai Z., Yan-ling Z., Jia-wan L., Xiang-qian L., Hong-wei C. Effects of chronic multiple stress on learning and memory and the expression of Fyn, BDNF, TrkB in the hippocampus of rats. Chinese Medical Journal 2007; 120 (8): 669-74.
30.Feng P, Guan Z, Yang X, Fang J. Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine. Brain Res. 2003; 991: 195-205.
31.Errico M., Crozier RA., Plummer MR., Cowen DS. 5-HT(7) receptors activate the mitogen activated protein kinase extracellular signal related kinase in cultured rat hippocampal neurons. Neurosci. 2001; 102: 361-7.
32.Giovannini MG, Blitzer RD, Wong T, Asoma K, Tsokas P, Morrison JH, Iyengar R, Landau EM. Mitogen-activated protein kinase regulates early phosphorylation and delayed expression of Ca2+/calmodulin-dependent protein kinase II in long-term potentiation. J. Neurosci. 2001; 21(18): 7053-62.
33.Mitogen-activated protein kinase regulates early phosphorylation and delayed expression of Ca2+/calmodulin-dependent protein kinase II in long-term potentiation. J. Neurosci. 2001; 21: 7053-62.
34.Mizuno M, Yamada K, He J, Nakajima A, Nabeshima T. Involvement of BDNF receptor TrkB in spatial memory formation. Mizuno M. et al. Learn. Mem. 2003; 10: 108-115.
*Correspondence address:
Dr. Amal Chandra Mondal
Asst. Professor in Physiology
Raja Peary Mohan College, Uttarpara, Hooghly
University of Calcutta,West Bengal: 712258,India.
Tel: +91 33 2663 4155/4245
Telefax: +91 33 2663 0881.
Research article:- Forensic Medicine and Toxicology
Shankar M Bakkannavar, MD DCL1, YP Raghavendra Babu, MD2*, Ashwinikumar, MD3, Vinod C Nayak, MD 4, Manjunath S, MD DCL 5, & Pradeep Kumar G, MD, Dip. Cr.L 6.
1Assistant Professor, Department of Forensic Medicine and Toxicology, Kasturba Medical College, Manipal University, Manipal, India.
2Associate Professor, Department of Forensic Medicine and Toxicology, Kasturba Medical College, Manipal University, Mangalore, India.
3Assistant Professor, 4,5 Associate Professor, 6 Professor & Head, Department of Forensic Medicine and Toxicology, Kasturba Medical College, Manipal University, Manipal,India.
Abstract:-
Subendocardial haemorrhage (SEH) is an atypical feature in many forensic autopsies, especially in victims of severe trauma. These haemorrhages are not only accompanied with blood loss due to trauma but also seen in non traumatic conditions such as poisoning and following transfusion of infected blood. In this retrospective study, we have analysed 1778 autopsy cases and investigated for the incidence of subendocardial haemorrhages in relation to their causes.
Key words:-Subendocardial haemorrhage; heart; autopsy; incidence.
References:-
1.Stephan Seidl. Subendocardial Hemorrhages. In: Forensic Pathology reiews. Edited by Michael Tsokos. Totowa, NewJersey: Humana press, 2005; (2): 293 – 306.
2.Meixner K. Hamorrhagische Diathesen, subendocardiale Blutungen, Verblutung. In: Neureuter F, Pietrusky F, Schutt E, editors. Handwo¨ rterbuch der gerichtlichen Medizin und naturwissenschaftlichen Kriminalistik. Berlin: Springer; 1940. p. 336, 731, 884.
3.Sheehan HL. Subendocardial hemorrhages in shock. Lancet 1940;1: 831–2.
4.Ponsold A. Lehrbuch der gerichtlichen Medizin. Stuttgart: Georg Thieme Verlag; 1950.
5.Mueller B. Gerichtliche Medizin. Heidelberg: Springer-Verlag; 1953.
6.Prokop O. Forensische Medizin. Berlin: VEB Verlag Volk und Gesundheit; 1966.
7.Knight B. Forensic Pathology. 3rd ed. London: Arnold; 2004.
8.Harruf RC. Subendocardial hemorrhage in forensic pathology autopsies. Am J Forensic Med Pathol 1993;14/4:248–58.
9.Keil K, Rothaemel T, Troeger HD. The subendocardial hemorrhages in respect to forensic medicine. Beitr Gerichtl Med 1991;49:45–53.
10.Rajs J. Left ventricular subendocardial hemorrhages. Study of their morphology, pathogenesis and prognosis. Forensic Sci 1997;10/2: 80–103. 11.Rajs J, Falconer B. Cardiac lesions in intravenous drug addicts. Forensic Sci Int 1997;13/3:193–209.
12.Seidl S. Subendocardial hemorrhages. In: Tsokos M, editor. Forensic pathology reviews, vol. 2. Totowa, New Jersey: Humana Press; 2005. p. 293–306.
13.Nicolic S et al. Amount of postmortem bleeding. An experimental autopsy study. Am. J. Forensic Med. Pathol. 2004;25:20–2.
14.Di Maio JD, Di Maio VJM. Forensic pathology. 2nd ed. Boca Raton: CRC Press; 2001.
15.Knight B. Forensic Pathology. London, United Kingdom: Arnoldt; 1996.
16.Chiu CJ, Mersereau WA, Scott HJ. Subendocardial hemorrhagic necrosis. The role of direct mechanical trauma on the endocardium. J Thorac Cardiovasc Surg. 1972;64:66-75.
17.Zhu BL, Fujita MQ, Quan L, et al. A sudden death due to cardiac conduction system injury from a blunt chest impact. Leg Med (Tokyo). 1999;1:266-9.
18.Harruff RC. Subendocardial hemorrhages in forensic pathology autopsies. Am J Forensic Med Patho. 1993;14:284-8.
19.Reinecke P, Notnagel C, Jehle J, et al. Circular hemorrhagic subendocardial necrosis after heart arrest and resuscitation. Z Kardiol. 2001;90:437-41.
20.Karch SB. Resuscitation-induced myocardial necrosis: catecholamines and defibrillation. Am J Forensic Med Pathol. 1987; 8:3-8.
21.Smith RP, Tomlinson BE. Subendocardial hemorrhages associated with intracranial lesions. J Pathol Bacteriol. 1954;68:327-34.
22.Koskelo P, Punsar S, Sipilae W. Subendocardial hemorrhage and E.C.G. changes in intracranial bleeding. BMJ. 1964;5396:1479-80.
23.Marion DW, Segal R, Thompson ME. Subarachnoid hemorrhage and the heart. Neurosurgery. 1986;18:101-6.
24.Kleinman WM, Krause SM, Hess ML. Differential subendocardial perfusion and injury during the course of gram-negative endotoxemia. Adv Shock Res. 1980;4:139-52.
25.Blood-Siegfried J, Nyska A, Lieder H, et al. Synergistic effect of influenza a virus on endotoxin-induced mortality in rat pups: a potential model for sudden infant death syndrome. Pediatr Res. 2002;52: 481-90.
26.Karch SB, Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathol Lab Med. 1988;112:225-30.
27.Price LM, Poklis A, Johnson DE. Fatal acetaminophen poisoning with evidence of subendocardial necrosis of the heart. J Forensic Sci. 1991;36:930-5.
28.Burton RR, MacKenzie WF. Cardiac pathology associated with high sustained +Gz:I. Subendocardial hemorrhage. Aviat Space Environ Med. 1976;47:711-7.
29.Sheehan HL. Subendocardial hemorrhages in shock. Lancet. 1940;1: 831-2.
30.McGovern VJ. Hypovolemic shock with particular reference to the myocardial and pulmonary lesions. Pathology. 1980;12:63-72.
31.Martin AM, Hackel DB, Entman ML, et al. Mechanisms in the development of myocardial lesions in hemorrhagic shock. Ann NY Acad Sci. 1969;156:79-90.
32.Bose T K, Basu RK, Biswas B, De JN, Majumdar BC, Datta S. Cardiovascular effects of yellow oleander ingestion. J Indian Med Assoc 1999;97:407-10.
33.Than T, Francis N, Tin Nu S, et al. Contribution of focal haemorrhage and microvascular fibrindeposition to fatal envenoming by Russell,s viper (Vipera russelli siamensis) in Burma. Acta Trop 1989; 46: 23-38.
34.Varga T, Szabo A. Herzveranderungen bei akutem intrakraniellen Druckanstieg. Z Rechtsmed 1978;80:311-8.
35.Keil W, Rothamel T, Troger HD.Subendokardiale Hamorrhagien aus forensisch medizinischer Sicht. Beitr Gerichtl Med 1991; 49:45-53.
*Correspondence address:
YP Raghavendra Babu.,
Associate Professor, Department of Forensic Medicine,
Kasturba Medical College, Mangalore - 575001,
Manipal University, Karnataka, India.
Tel : +91 824 2422271(Office), +91 9844884949 (Mobile)
Fax : +91 824 2428183.
Case report:-
1Syed Hassan,1Yaser Alkhatib, 1Zahrae Sandouk & 2SyedAmer.
1Department of Internal Medicine, HenryFordHospital, Detroit-USA.
2Department of Internal Medicine, BrookdaleUniversity hospital and medical center, New York-USA.
Abstract :- Patients with congenital bleeding disorders now enjoy prolonged life expectancy secondary to better availability of comprehensive health care and treatment options. However this comes at a price of increase in age related co morbidities. There is limited data from the large observational studies on the prevalence rate of cardiovascular and cerebrovascular disease in this bleeding population. More so, there is little to none available data on the management of these age related diseases. In this article, we attempted to review the management of cerebrovascular accidents among the patients with Von Willebrand disease at our institution.
Key Words:- Cardiovascualr, cerebrovascular accident, VonWillebrand disease(VWF).
References:-
1.Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thrombosis and haemostasis. Aug 2004;92(2):298-304.
2.Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta haematologica. 2006;116(2):120-5.
3.Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thrombosis research. Jan 2011;127 Suppl 2:S22-5.
4.Fransen van de Putte DE, Fischer K, Makris M, et al. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and haemostasis. Jan 8 2013;109(1):16-23.
5.Biere-Rafi S, Zwiers M, Peters M, et al. The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review. The Netherlands journal of medicine. May 2010;68(5):207-14.
6.Franchini M, Coppola A. Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management. Seminars in thrombosis and hemostasis. Mar 2012;38(2):185-99.
7.Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of thrombosis and haemostasis : JTH. Oct 2006;4(10):2103-14.
8.Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke; a journal of cerebral circulation. Nov 2006;37(11):2672-7.
9.Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke; a journal of cerebral circulation. Oct 2010;41(10):2151-6.
10.Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arteriosclerosis, thrombosis, and vascular biology. Nov 1997;17(11):3321-5.
11.De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke; a journal of cerebral circulation. Feb 2012;43(2):599-606.
12.Qureshi W, Hassan S, Dabak V, Kuriakose P. Thrombosis in VonWillebrand disease. Thrombosis research. Nov 2012;130(5):e255-8.
13.Silwer J, Cronberg S, Nilsson IM. Occurrence of arteriosclerosis in von Willebrand's disease. Acta medica Scandinavica. Oct 1966;180(4):475-84.
14.Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine. Jul 1983;62(4):248-55.
Copyright © 2013 Hassan Syed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
*Correspondence address:
Syed A. Hassan.,
Department of Internal Medicine,
2799 West Boulevard,
Detroit-48202, Michigan-USA.
Phone no: 773-681-6720
Fax: 313-916-1888.
Research article:-
Soumendra Sahoo1* & Padma Lochan.Nayak 2
1 Melaka Manipal Medical College, Melaka, Malaysia.
2 P.L.Nayak Research Foundation, Centre for Nanoscience and Technology, Synergy Institute of Technology, Bhubaneswar, Odisha ,India.
Abstract:- Chitosan-Gelatin/montmorillonite Cloisite 30 B (MMT) hybrid nanocomposites were prepared by blending chitosan-Gelatin with Cloisite 30B in aqueous solution. The nano composites were characterized by using FTIR, SEM and XRD analysis. From the FTIR spectra the various groups present in the chitosan-Gelatin blend were monitored. The homogeneity, morphology and crystallinity of the blends were ascertained from SEM and XRD data, respectively. The results indicated that an intercalated or partially exfoliated nanocomposite could be achieved, and the properties of the composite were significantly improved. The drug release kinetics was investigated using ketorolac as the drug. The kinetics of the drug delivery system has been systematically studied. Drug release kinetics was analyzed by plotting the cumulative release data vs. time by fitting to an exponential equation which indicated the non-Fickian type of kinetics. The drug release was investigated at different pH medium and it was found that the drug release depends upon the pH medium as well as the nature of matrix.
Key Words:- Chitosan,Gelatin, Cloisite 30 B, Ketorolac, Drug delivery, Kinetics.
References:-
1.Smart, J. D. The basics and underlying mechanisms of mucoadhesion. Adv.Drug Del. Rev.2005;57(11):1556-68.
2.Hägerström, H.; Edsman, K.; Strømme, M. Low- Frequency Dielectric Spectroscopy as a Tool for Studying the Compatibility between Pharmaceutical Gels and Mucus Tissue. J. Pharm. Sci.2003;92(9):1869-81.
3.Woodley, J. Bioadhesion, new possibilities for drug administration? Clin. Pharmacokinet.2001;40(2):77-84.
4.Andrews, G. P.; Laverty, T. P.; Jones, D. S. Mucoadhesive polymeric platforms for controlled drug delivery, Eur. J. Pharm. Biopharm.2008;71(3):505-18.
5.Sahoo Debashish., Sahoo sarmila., Mohanty P.,Sasmal S and Nayak P.L Chitosan: a new versatile biopolymer for various applications.J.designed monomer and polymer. 2009; 12:377-404.
6. Sahoo Debashish. and Nayak P.L.Release Behaviour of Chloramphenicol From N-Acyl Derivatives of Chitosan. NanoTrends: A Journal of Nanotechnology and Its Applications, 2012; 1:01-09.
7.Malesu V. K., Sahoo Debashish. and Nayak P.L. Chitosan–Sodium Alginate Nanocomposites Blended with Cloisite 30B As a Novel Drug Delivery System for Anticancer Drug Curcumin , International Journal of Applied biology and Pharmaceutical Technology.2011;2(3):402-11.
8.Sahoo Debashish. and Nayak P.L. Synthesis and Characterization of Chitosan Nanocomposite Film for controlled Release of Ofloxacin. Journal of Applied Polymer Science 2011;123(5):2588-94.
9.Nayak P.L. & Sahoo Debashish. Chitosan-alginate composites blended with cloisite 30B as a noveldrug delivery system for anticancer drug paclitaxel. International Journal of Plastics Technology.2011;15(1):68-81.
10.Sahoo Debashish., Sahoo sarmila., Das J., Dangar T.K., and Nayak P.L. Antibacterial Activity of Chitosan Cross Linked with Aldehydes and Blended with Cloisite 30 B.NanoTrends: A Journal of Nanotechnology and Its Applications 2011;10(2):1-9.
11.Sahoo Sarmila., Sasmal Abhisek., Sahoo Debashish., Nayak P.L.Synthesis and Characterization of Chitosan-Polycaprolactone Blended with Organoclay for Control Release of Doxycycline.Journal of Applied Polymer Science2010;118(6):3167-75 .
12.Book Chapter on Chitosan : Sahoo Debasish . and Nayak P.L., Chitosan: The Most Valuable Derivative of Chitin (Chapter 6) in Biopolymers: Biomedical and Environmental Application, (129–166), Scrivener Publishing LLC, (ISBN: 9780470639238 ).
13. Lee, J. W.; Park, J. H.; Robinson, J. R. Bioadhesive-based dosage forms: The next generation. J. Pharm. Sci 2000;89(7):850-66.
14.Nanda P K, Rao K K, Kar R K and Nayak P L,Biodegradable polymers: Part VI. Biodegradable plastics of soy protein isolate modified with thiourea. Journal of Thermal Analysis and Calorimetry 2007;89(3):935–40.
15. Draye J P, DelaeyB,Voorde A V D, Bulcke A V D, Reu B D,and Schacht E, Biomaterials1998;19:1677.
16.Maeda T, Motoyoshi and H. Jpn, J PolymSciTechnol 1996; 53:155.
17.Fakirov S, Sarac Z, Anbar T, Boz B, Bahar I, Evstatiev M, Apostolov A. A, Mark J. E and Kloczkowski A, Colloid PolymSci 1996; 274: 334.
18.Fakirov S, SaracZ, Anbar T, Boz B, BaharI,Evstatiev M, ApostolovA. A, MarkJ. E and Kloczkowski A, ColloidPolymSci 1997; 275: 307.
19.Zhao W Y, Kloczkowski A, Mark J. E, Erman Band Bahar I and Chemtech March.1996; 26:30.
20.BigiA,Panzavolta S, Roveri N, Biomaterials.1998;19:739.
21.Lin F H, Yao C. H and SunJ. S, Biomaterials.1998; 19: 905. 22.Wan Y. Z, Wang Y. L, Luo H. L,Cheng G. X and Yao K. D. J ApplPolymSci.2000; 75:987.
23.Andrade JR, Maslanka M, Maneatis T, Bynum L, Burchomore M. The use of Ketorolac tromethamine in the management of post operative pain. Orthopedics 1994; 17:157–66. PMid:8190679
24.Shankar C, Mishra M. Development and in-vitro evaluation of gelatin A microspheres of Ketorolac tromethamine for intranasal administration. Acta Pharm 2003; 53:101–10. PMid: 14764244
25.Shyamala B, Sanmathi BS. Poly(lactic acid) microspheres of Ketorolac tromethamine for parenteral controlled drug delivery system. Indian J Pharm Sci 2001; 63: 538–40.
26.Shyamala B, Sanmathi BS. Influence of manufacturing parameters and the release profile of Ketorolac tromethamine from poly (Lactide-co-glycolide) microspheres. Indian Drugs. 2001; 38: 383–5.
27.Kulkarni A.R., Soppimath K.S., and Aminabhavi T.M. Controlled Release of Diclofenac Sodium from Sodium Alginate Beads Crosslinked with Glutaraldehyde,” Phar- maceuticaActaHelvetiae 1999;74: 29-36. doi:10.1016/0168-3659(87)90035-6.
28.Vimala K., Mohan Y.M., Varaprasad K., Redd N.N., RavindraS.,Naidu N.S.,.Raju K.M., (2011).Fabrication of Cur- cumin Encapsulated Chitosan-PVA Silver Nanocompo- site Films for Improved Antimicrobial Activity,Journal of Biomaterials and Nanobiotechnology,2011;255-64 :doi:10.4236/jbnb.2011.21008.
29.Singla A.K., Garg A.and Aggarwal D. Paclitaxel and its formulations,” International Journal of Pharmaceutics, 2002;235(1):179-92. doi:10.1016/S0378-5173(01)00986-3 .
30.Singla A.K.and Chawla M.,(2001). Chitosan: Some Pharma-ceutical and Biological Aspects—an Update, Journal of Pharmacy and Pharmacology 2001; 53(8):1047-67. doi:10.1211/0022357011776441.
Copyright © 2013 Soumendra Sahoo & Padma L.Nayak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
*Correspondence address:
Prof Dr Soumendra Sahoo.,
Head, Ophthalmology,
Melaka Manipal Medical College, Melaka 75150 Malaysia.